PCMA: Policymakers should focus on biogeneric approval

11/18/2009 | Drug Store News

Responding to an article published by The New York Times that said drug companies have raised prices even though the Consumer Price Index has dropped, the Pharmaceutical Care Management Association called for policymakers to ensure that there is a regulatory process through which biogenerics can receive marketing approval. "Increased choice and competition generated by pharmacy benefit managers has been pivotal in driving prescription-drug trend to historic lows, while expanding consumers' access to drug and pharmacy choices," PCMA said in a statement.

View Full Article in:

Drug Store News